Cambrex Co. (CBM) Receives Average Rating of “Hold” from Analysts
Cambrex Co. (NYSE:CBM) has received a consensus rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $62.33.
CBM has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of Cambrex from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. ValuEngine raised shares of Cambrex from a “hold” rating to a “buy” rating in a report on Tuesday, August 22nd. Finally, Craig Hallum reaffirmed a “buy” rating and set a $60.00 price objective (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st.
Shares of Cambrex (NYSE CBM) opened at $48.20 on Monday. Cambrex has a twelve month low of $42.55 and a twelve month high of $62.95. The stock has a market cap of $1,579.90, a price-to-earnings ratio of 15.21, a P/E/G ratio of 1.08 and a beta of 2.26.
In other Cambrex news, CEO Steven M. Klosk sold 4,000 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $54.96, for a total transaction of $219,840.00. Following the transaction, the chief executive officer now directly owns 87,328 shares of the company’s stock, valued at $4,799,546.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 2.48% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in Cambrex by 0.5% during the second quarter. BlackRock Inc. now owns 4,023,607 shares of the biotechnology company’s stock valued at $240,409,000 after purchasing an additional 20,652 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Cambrex by 1.0% during the third quarter. Dimensional Fund Advisors LP now owns 1,343,468 shares of the biotechnology company’s stock valued at $73,891,000 after purchasing an additional 13,214 shares in the last quarter. FMR LLC lifted its holdings in Cambrex by 19.1% during the second quarter. FMR LLC now owns 1,070,645 shares of the biotechnology company’s stock valued at $63,971,000 after purchasing an additional 171,559 shares in the last quarter. State Street Corp lifted its holdings in Cambrex by 5.1% during the second quarter. State Street Corp now owns 779,820 shares of the biotechnology company’s stock valued at $46,600,000 after purchasing an additional 37,669 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Cambrex by 3.7% during the second quarter. Northern Trust Corp now owns 566,302 shares of the biotechnology company’s stock valued at $33,837,000 after purchasing an additional 19,955 shares in the last quarter.
WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/12/04/cambrex-co-cbm-receives-average-rating-of-hold-from-analysts.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Stock Ratings for Cambrex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Co. and related stocks with our FREE daily email newsletter.